Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

120.78 -2.38 (-1.93%)
Streaming Delayed Price Updated: 12:13 PM EDT, May 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
51 52 Next >
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: EchoStar Corporation (Nasdaq - SATS), Sovos Brands, Inc. (Nasdaq - SOVO), Reata Pharmaceuticals, Inc. (Nasdaq - RETA), Amedisys, Inc. (Nasdaq – AMED)
From Brodsky & Smith LLC
Via GlobeNewswire
Looking Into Biogen's Recent Short Interest
Via Benzinga
Is Sage Therapeutics a Contrarian Buy?
A regulatory setback weighed heavily on the drugmaker's shares Monday. 
Via The Motley Fool
DraftKings To Rally Over 38%? Here Are 10 Other Analyst Forecasts For Tuesday
Piper Sandler raised the price target for Chegg, Inc. (NYSE: CHGG) from $11 to $13. Piper Sandler analyst Arvind Ramnani maintained a Neutral rating. Chegg shares rose 19.9% to $12.03 in pre-market... 
Via Benzinga
Biogen Unusual Options Activity For August 02
Via Benzinga
Here's How Much You Would Have Made Owning Biogen Stock In The Last 15 Years
Via Benzinga
Health Care Company Biogen Announces Acquisition of Reata Pharmaceuticals
Via Benzinga
What More Can Support Biogen/Sage's Zuranolone Resubmission: Analysts See Uncertain Road Ahead
The FDA approved Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc's (NASDAQ: BIIB) Zurzuvae (zuranolone) 50 mg for adults with postpartum depression (PPD) but issued a Complete Response Letter 
Via Benzinga
Dow Rises Over 300 Points To Start The Week
The Dow Jones Industrial Average was last seen up 308 points, as the blue-chip index looks to start the week on a high note following its recent losses. 
Via Talk Markets
FDA's Rejection of Sage/Biogen's Zuranolone Boosts Prospects for Axsome's Auvelity, Analyst Says
Axsome Therapeutics Inc (NASDAQ: AXSM) reported Q2 sales of $46.7 million, beating the consensus of $40.19 million.  
Via Benzinga
PayPal Unveils USD-Backed Stablecoin, Trucking Firm Yellow Corp Files For Bankruptcy, FDA Approves First Oral Treatment For Postpartum Depression: Today's Top Stories
Benzinga 
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fiesta Restaurant Group, Inc. (Nasdaq - FRGI), Veritiv Corporation (NYSE - VRTV), New Relic, Inc. (NYSE - NEWR), Reata Pharmaceuticals, Inc. (Nasdaq - RETA)
From Brodsky & Smith LLC
Via GlobeNewswire
Why Sage Lost Half Its Value After The FDA Approved Its Depression Drug
The company gained approval for the first oral treatment for postpartum depression. 
Via Investor's Business Daily
FDA Approves Sage Therapeutics/Biogen's Zuranolone For One Type Of Depression, Rejects For Another
The FDA approved Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc's (NASDAQ: BIIB) Zurzuvae (zuranolone) 50 mg for adults with  
Via Benzinga
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
From Sage Therapeutics, Inc.
Via Business Wire
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
From Biogen Inc.
Via GlobeNewswire
3 ‘Strong Buy’ Biotech Stocks You Should Be Loading Up On Now
Biotech stocks can be a lucrative investment opportunity, these three biotech stocks to buy now are among analyst favorites. 
Via InvestorPlace
Buy Alert: 3 Biotech Stocks Nearing Super Attractive Entry Points
Investors looking to give their portfolio a boost should consider one of these leading biotech names, which are undervalued right now. 
Via InvestorPlace
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: New Relic, Inc. (NYSE - NEWR), Reata Pharmaceuticals, Inc. (Nasdaq - RETA), Talaris Therapeutics, Inc. (Nasdaq - TALS), Inpixon® (Nasdaq - INPX)
From Brodsky & Smith LLC
Via GlobeNewswire
Biogen's Just Made Its Biggest Acquisition. Here's What You Need to Know.
Biogen also recently announced a plan to cut costs and focus investment on high-growth areas. 
Via The Motley Fool
Rising Stars, Falling Trends: July's Industry ETF Winners And Losers
Via Benzinga
Better Alzheimer's Drug Stock: Eli Lilly vs. Biogen
By 2024, their medicines will likely be competing on the market, and one might win. 
Via The Motley Fool
Could This Stock Be the Next Biotech Buyout?
A buyout deal recently pushed Reata Pharmaceuticals stock 53% higher in a single trading session, leading investors to wonder who's next. 
Via The Motley Fool
3 Millionaire-Maker Biotech Stocks to Buy Before the Window Closes
Here are three millionaire maker drug stocks from companies whose drugs could make truly staggering profits. 
Via InvestorPlace
Biotech Battlefields: 3 Stocks to Watch Amid Wall Street Turmoil
There is opportunity in a crisis. Key biotech stocks amid turmoil could be the greatest deals on the market today. 
Via InvestorPlace
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Reata Pharmaceuticals, Inc. (Nasdaq – RETA), Talaris Therapeutics, Inc. (Nasdaq – TALS), Inpixon® (Nasdaq – INPX), Amedisys, Inc. (Nasdaq – AMED)
From Brodsky & Smith LLC
Via GlobeNewswire
Stock Market Rallies Amid Huge Earnings, Fed Rate Hike, Inflation Data: Weekly Review
Despite Thursday's downside reversal, the major indexes had a solid advance. 
Via Investor's Business Daily
Biogen (NASDAQ: BIIB) Acquires Reata (NASDAQ: RETA) to Boost its Neurological Therapeutics Portfolio, Including SKYCLARYS®
Reata's Acquisition to Propel Biogen's Growth Strategy Biogen Inc. (NASDAQ: BIIB) and Reata Pharmaceuticals, Inc. (NASDAQ: RETA) have announced a 
Via Spotlight Growth
Reata's Acquisition Fits Biogen's Strategy Despite High Cost: Analyst Says High Level Regulatory Scrutiny Not Anticipated
Earlier today, Biogen Inc (NASDAQ: BIIB) agreed to acquire Reata Pharmaceuticals Inc (NASDAQ: RETA) for $172.50 per share in cash, reflecting an enterprise value of  
Via Benzinga
Why Is Reata Pharmaceuticals (RETA) Stock Up 53% Today?
Reata Pharmaceuticals (RETA) stock is soaring higher on Friday as investors react to an acquisition deal with Biogen (BIIB). 
Via InvestorPlace
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
51 52 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.